Dynamics of organ damage markers during inhalation of subanesthetic doses of xenon in patients receiving systemic anticancer therapy: a randomized controlled trial

Authors:
Open Access
Publisher website
Google Scholar
Abstract
INTRODUCTION: Organ toxicity of anticancer treatment remains a significant problem in comorbid patients. Xenon has organoprotective properties, but its clinical use during chemotherapy has been insufficiently studied. OBJECTIVE: To assess changes in organ damage markers, as well as the safety and tolerability of inhaled subanesthetic xenon in patients receiving systemic anticancer therapy. MATERIALS AND METHODS: A prospective randomized controlled study was conducted. Forty-four women with breast, ovarian, or uterine corpus cancer were randomized; 41 completed the intervention stage and were analyzed: 20 in the xenon group and 21 in the control group. The xenon group received three 30-minute inhalations of an oxygen-xenon mixture containing 27–34 % xenon on Days 1, 3, and 5 from chemotherapy initiation; controls received oxygen-nitrogen inhalations. The primary outcome was change in high-sensitivity cardiac troponin T from baseline to Day 15. Secondary outcomes included N-terminal pro-B-type natriuretic peptide (NT-proBNP), S100B protein, syndecan-1, echocardiographic parameters, kidney and liver function tests; safety was assessed by adverse events. RESULTS: Change in high-sensitivity cardiac troponin T from baseline to Day 15 was 8.94 [4.50; 13.30] pg/mL in the control group and 1.01 [−0.09; 1.98] pg/mL in the xenon group (p < 0.001). In the baseline-adjusted model, the between-group difference at Day 15 was β = −7.90 (95% CI: −12.85; −2.94; p = 0.003). The adjusted between-group difference in left ventricular ejection fraction change was +4.66 % (95% CI: 2.4; 6.9; p < 0.001). Significant within-group changes in NT-proBNP and S100B were observed in the control group, whereas no significant changes were observed in the xenon group. CONCLUSIONS: Three 30-minute inhalations of an oxygen-xenon mixture containing 27–34 % xenon were well tolerated and were associated with preliminary differences in changes in markers of subclinical organ damage. These findings require confirmation in larger studies with longer follow-up.

This publication has 33 references indexed in Scilit: